Northern Trust
GMAB icon

Northern Trust’s Genmab GMAB Stock Holding History

Northern Trust’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.2M Sell
916,600
-33,934
-4% -$902K ﹤0.01% 1663
2026
Q1 		$25.5M Sell
950,534
-6,495
-0.7% -$195K ﹤0.01% 1516
2025
Q4 		$29.5M Buy
957,029
+74,732
+8% +$2.33M ﹤0.01% 1423
2025
Q3 		$27.1M Buy
882,297
+78,695
+10% +$1.92M ﹤0.01% 1501
2025
Q2 		$16.6M Buy
803,602
+178,489
+29% +$3.66M ﹤0.01% 1764
2025
Q1 		$12.2M Buy
625,113
+25,732
+4% +$540K ﹤0.01% 1923
2024
Q4 		$12.5M Buy
599,381
+94,858
+19% +$2.08M ﹤0.01% 1991
2024
Q3 		$12.3M Sell
504,523
-14,861
-3% -$397K ﹤0.01% 1952
2024
Q2 		$13.1M Sell
519,384
-34,844
-6% -$988K ﹤0.01% 1835
2024
Q1 		$16.6M Buy
554,228
+15,198
+3% +$446K ﹤0.01% 1715
2023
Q4 		$17.2M Sell
539,030
-20,014
-4% -$628K ﹤0.01% 1726
2023
Q3 		$19.7M Buy
559,044
+254,042
+83% +$9.68M ﹤0.01% 1550
2023
Q2 		$11.6M Buy
305,002
+3,308
+1% +$132K ﹤0.01% 1953
2023
Q1 		$11.4M Sell
301,694
-3,344
-1% -$129K ﹤0.01% 1928
2022
Q4 		$12.9M Sell
305,038
-25,527
-8% -$1.05M ﹤0.01% 1834
2022
Q3 		$10.6M Buy
330,565
+20,514
+7% +$720K ﹤0.01% 1925
2022
Q2 		$10.1M Sell
310,051
-720
-0.2% -$23.3K ﹤0.01% 2030
2022
Q1 		$11.2M Sell
310,771
-4,332
-1% -$149K ﹤0.01% 2074
2021
Q4 		$12.5M Buy
315,103
+5,475
+2% +$228K ﹤0.01% 2081
2021
Q3 		$13.5M Sell
309,628
-59,865
-16% -$2.69M ﹤0.01% 2068
2021
Q2 		$15.1M Sell
369,493
-209,474
-36% -$8.08M ﹤0.01% 2094
2021
Q1 		$19M Buy
578,967
+264,230
+84% +$9.94M ﹤0.01% 1858
2020
Q4 		$12.8M Buy
314,737
+15,178
+5% +$567K ﹤0.01% 2089
2020
Q3 		$11M Buy
299,559
+7,693
+3% +$278K ﹤0.01% 2063
2020
Q2 		$9.89M Buy
291,866
+734
+0.3% +$20K ﹤0.01% 2104
2020
Q1 		$6.17M Buy
291,132
+171,934
+144% +$3.83M ﹤0.01% 2181
2019
Q4 		$2.66M Buy
119,198
+55,069
+86% +$1.2M ﹤0.01% 2947
2019
Q3 		$1.3M Buy
+64,129
New +$1.26M ﹤0.01% 3306

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Northern Trust's GMAB Position: Q2 2026 in Review

Northern Trust reduced its Genmab (GMAB) stake by 3.6% in Q2 2026, selling an estimated $902K and leaving 916,600 shares worth $25.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1663.

Northern Trust first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. The position peaked at $29.5M in Q4 2025. 292 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Northern Trust held 916,600 shares of Genmab worth $25.2M as of Q2 2026.
  • Northern Trust sold 33,934 Genmab shares in Q2 2026, an estimated $902K.
  • Genmab made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #1663 holding.
  • Northern Trust first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • Northern Trust's Genmab position peaked at $29.5M in Q4 2025.
  • 292 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.